Bionomics (NASDAQ:BNOX) Shares Down 4.5% – Here’s Why

Bionomics Limited (NASDAQ:BNOX)’s share price traded down 4.5% during mid-day trading on Thursday . The stock traded as low as $0.24 and last traded at $0.25. 440,386 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 2,841,457 shares. The stock had previously closed at $0.26.

Analysts Set New Price Targets

Separately, William Blair reaffirmed an “outperform” rating on shares of Bionomics in a report on Friday, November 15th.

Bionomics Stock Down 2.9 %

The company has a fifty day moving average price of $0.29 and a two-hundred day moving average price of $0.52.

Institutional Investors Weigh In On Bionomics

An institutional investor recently bought a new position in Bionomics stock. Armistice Capital LLC acquired a new position in shares of Bionomics Limited (NASDAQ:BNOX) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics at the end of the most recent quarter. Institutional investors own 15.90% of the company’s stock.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.